G
Global Blood Therapeutics
Biotech & Life Sciences · San Francisco, United States · Founded 2012
A clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities MoreLess
Global Blood Therapeutics (GBT), now part of Pfizer, is dedicated to discovering, developing, and delivering innovative treatments for sickle cell disease (SCD), a lifelong inherited blood disorder affecting hemoglobin in red blood cells. GBT's core product, Oxbryta (voxelotor), has been approved by the U.S. FDA for SCD patients as young as 4 years old. The company operates in the biopharmaceutical sector, primarily serving patients, their families, and healthcare professionals. GBT's business model focuses on research and development, clinical trials, and regulatory approvals to bring new therapies to market. Revenue is generated through the sale of its approved treatments and potential future therapies. GBT is committed to changing the treatment paradigm in SCD through continuous innovation and strong community advocacy.
Keywords: sickle cell disease, biopharmaceutical, Oxbryta, voxelotor, FDA approval, innovative treatments, clinical trials, hemoglobin, inherited blood disorder, patient advocacy.
Company overview
Global Blood Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2012
- Headquarters
- San Francisco, United States
- Employees
- 73
- Open positions
- None listed
- Dealroom signal
- 63.7
Valuation & funding
Global Blood Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Aug 2022 | $5.4B | $5.4B | Pfizer | ↗ |
| IPO✓Exit | Aug 2015 | $120M | $350M | Undisclosed | ↗ |
| SERIES B✓Equity / VC | Jan 2015 | $48M | $192M | Deerfield · Sabby Capital · RA Capital Management · Wellington Management | — |
| SERIES A✓Equity / VC | Jun 2012 | $41M | $163M | Third Rock Ventures | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Global Blood Therapeutics website traffic
Latest recorded traffic for Global Blood Therapeutics is 800 monthly website visits, up 90.5% over the last three months. Global Blood Therapeutics's team declined 24% over the past year.
Comparisons
Global Blood Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Global Blood Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Global Blood Therapeutics has talent and traffic
team presence
In the news
Latest news about Global Blood Therapeutics
Recent press, funding announcements, and product moves mentioning Global Blood Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Global Blood Therapeutics
An AI-synthesized read of the highest-engagement posts about Global Blood Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Global Blood Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.